Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer

Cancer Science

Volumn 102, Issue 1, 2011, Pages 166-174

  Kawakami, Kazuyuki ^a   Matsunoki, Aika ^a,b   Kaneko, Mami ^a,b   Saito, Kenichiro ^a,b   Watanabe, Go ^b   Minamoto, Toshinari ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARMOFUR; DOXIFLURIDINE; FLUOROURACIL; HISTONE H2AX; TEGAFUR; URACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL STRAIN CACO 2; CELL STRAIN HCT116; COLORECTAL CANCER; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; DNA STRUCTURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG INTERSPERSED NUCLEAR ELEMENT 1; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; NORTHERN BLOTTING; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RNA INTERFERENCE; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, PAIR 18; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; FLUOROURACIL; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PHENOTYPE;

EID: 78650223983     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01776.x     Document Type: Article

References (42)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
2. Shen L, Catalano PJ, Benson AB III, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res 2007; 13: 6093-8.
3. Joensuu EI, Abdel-Rahman WM, Ollikainen M, Ruosaari S, Knuutila S, Peltomaki P. Epigenetic signatures of familial cancer are characteristic of tumor type and family category. Cancer Res 2008; 68: 4597-605.
4. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
5. Deininger PL, Moran JV, Batzer MA, Kazazian HH Jr. Mobile elements and mammalian genome evolution. Curr Opin Genet Dev 2003; 13: 651-8.
6. Kazazian HH Jr. Mobile elements: drivers of genome evolution. Science 2004; 303: 1626-32.
7. Sassaman DM, Dombroski BA, Moran JV et al. Many human L1 elements are capable of retrotransposition. Nat Genet 1997; 16: 37-43.
8. Brouha B, Schustak J, Badge RM et al. Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci U S A 2003; 100: 5280-5.
9. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004; 32: e38.
10. Rodriguez J, Frigola J, Vendrell E et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 2006; 66: 8462-9468.
11. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-206.
12. Sheffer M, Bacolod MD, Zuk O et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009; 106: 7131-6.
13. Kawakami K, Jin M, Saito K et al. Methylation level of LINE-1 repeats as a prognostic factor for the patients with primary colorectal cancer [abstract 991]. Proc Am Assoc Cancer Res 2008; 49: 232.
14. Ogino S, Nosho K, Kirkner GJ et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008; 100: 1734-8.
15. Estecio MR, Gharibyan V, Shen L et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE 2007; 2: e399.
16. Ogino S, Kawasaki T, Nosho K et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008; 122: 2767-73.
17. Jover R, Zapater P, Castells A et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55: 848-55.
18. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9: 2898-903.
19. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-26.
20. Sobin LH, Wittekind Ch, eds. International Union Against Cancer (UICC): ''TNM Classification of Malignant Tumors'', 6th edn. New York: Wiley, 2002.
21. Kawakami K, Brabender J, Lord RV et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000; 92: 1805-11.
22. Iacopetta B, Grieu F, Phillips M et al. Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa. Cancer Sci 2007; 98: 1454-60.
23. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
24. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS ONE 2010; 5: e9393.
25. Buhard O, Cattaneo F, Wong YF et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 2006; 24: 241-51.
26. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, Minamoto T. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res 2010; 16: 2418-26.
27. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna/Austria: R Foundation for Statistical Computing, 2008, ISBN 3-900051-07-0.
28. Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S, Kim YS. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 2005; 11: 8564-9.
29. Feng Q, Moran JV, Kazazian HH Jr, Boeke JD. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell 1996; 87: 905-16.
30. Bonner WM, Redon CE, Dickey JS et al. γH2AX and cancer. Nat Rev Cancer 2008; 8: 957-67.
31. Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005; 24: 1403-11.
32. Kunz C, Focke F, Saito Y et al. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 2009; 7: e91.
33. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073-87.
34. Barault L, Charon-Barra C, Jooste V et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 2008; 68: 8541-6.
35. Kim JH, Shin SH, Kwon HJ, Cho NY, Kang GH. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 2009; 455: 485-94.
36. Dahlin AM, Palmqvist R, Henriksson ML et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res 2010; 16: 1845-55.
37. Ogunbiyi OA, Goodfellow PJ, Herfarth K et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998; 16: 427-33.
38. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-6.
39. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452: 564-70.
40. Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-7.
41. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004-7.
42. Watanabe T, Sano M, Takashima S et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. J Clin Oncol 2009; 27: 1368-74.